-
Je něco špatně v tomto záznamu ?
Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma--next step toward reliable non-invasive prenatal diagnostics
L. Zejskova, T. Jancuskova, K. Kotlabova, J. Doucha, I. Hromadnikova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- alkoholoxidoreduktasy krev genetika MeSH
- DNA krev MeSH
- lidé MeSH
- metylace DNA genetika MeSH
- nádorové supresorové proteiny krev genetika MeSH
- plod MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- prenatální diagnóza metody MeSH
- protein oblasti určující pohlaví na chromozomu Y krev genetika MeSH
- retrospektivní studie MeSH
- senzitivita a specificita MeSH
- těhotenství krev genetika MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- těhotenství krev genetika MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
We determined the feasibility of universal fetal marker detection in maternal circulation. Using real-time PCR, we compared the levels of fetal (SRY and hypermethylated RASSF1A) and total (GLO gene and total RASSF1A) extracellular DNA and fractions of extracellular fetal DNA (SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A) in maternal circulation. Sensitivity and specificity reached 100% as the fetal-specific hypermethylated RASSF1A sequence was detected in all 151 examined plasma samples derived from 70 normal pregnancies with a singleton male (n=51) or female (n=19) fetus sampled throughout gestation and absent in non-pregnant individuals (n=29). A strong positive correlation was observed between fetal-derived hypermethylated RASSF1A and SRY (ρ=0.66, P<0.001), total RASSF1A and GLO (ρ=0.65,P<0.001), SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A ratio (ρ=0.62, P<0.001) in maternal plasma. The results indicate that a universal fetal marker could be useful not only for the confirmation of the presence of fetal cell-free DNA in maternal plasma but could enable quantification of cell-free fetal DNA in pregnancy associated disorders, independently of the sex of the fetus.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026092
- 003
- CZ-PrNML
- 005
- 20121207101900.0
- 007
- ta
- 008
- 120817e20100922xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.yexmp.2010.09.002 $2 doi
- 035 __
- $a (PubMed)20868679
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zejskova, L $u Department of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague, Czech Republic. lenka.zej@centrum.cz
- 245 10
- $a Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma--next step toward reliable non-invasive prenatal diagnostics / $c L. Zejskova, T. Jancuskova, K. Kotlabova, J. Doucha, I. Hromadnikova,
- 520 9_
- $a We determined the feasibility of universal fetal marker detection in maternal circulation. Using real-time PCR, we compared the levels of fetal (SRY and hypermethylated RASSF1A) and total (GLO gene and total RASSF1A) extracellular DNA and fractions of extracellular fetal DNA (SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A) in maternal circulation. Sensitivity and specificity reached 100% as the fetal-specific hypermethylated RASSF1A sequence was detected in all 151 examined plasma samples derived from 70 normal pregnancies with a singleton male (n=51) or female (n=19) fetus sampled throughout gestation and absent in non-pregnant individuals (n=29). A strong positive correlation was observed between fetal-derived hypermethylated RASSF1A and SRY (ρ=0.66, P<0.001), total RASSF1A and GLO (ρ=0.65,P<0.001), SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A ratio (ρ=0.62, P<0.001) in maternal plasma. The results indicate that a universal fetal marker could be useful not only for the confirmation of the presence of fetal cell-free DNA in maternal plasma but could enable quantification of cell-free fetal DNA in pregnancy associated disorders, independently of the sex of the fetus.
- 650 _2
- $a alkoholoxidoreduktasy $x krev $x genetika $7 D000429
- 650 _2
- $a DNA $x krev $7 D004247
- 650 _2
- $a metylace DNA $x genetika $7 D019175
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a plod $7 D005333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a těhotenství $x krev $x genetika $7 D011247
- 650 _2
- $a prenatální diagnóza $x metody $7 D011296
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a protein oblasti určující pohlaví na chromozomu Y $x krev $x genetika $7 D051876
- 650 _2
- $a nádorové supresorové proteiny $x krev $x genetika $7 D025521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jancuskova, T
- 700 1_
- $a Kotlabova, K
- 700 1_
- $a Doucha, J
- 700 1_
- $a Hromadnikova, I
- 773 0_
- $w MED00001738 $t Experimental and molecular pathology $x 1096-0945 $g Roč. 89, č. 3 (20100922), s. 241-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20868679 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207101934 $b ABA008
- 999 __
- $a ok $b bmc $g 948134 $s 783438
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 89 $c 3 $d 241-7 $e 20100922 $i 1096-0945 $m Experimental and molecular pathology $n Exp Mol Pathol $x MED00001738
- LZP __
- $a Pubmed-20120817/10/04
